Vertex Pharmaceuticals (VRTX) is a top biotech pick, with strong earnings, diverse pipelines, and growth prospects. See here ...
Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S.
Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the company's innovation. The company recently has expanded into another area, too, and ...
Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for controversial ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly ...
The New York Times will take down Vertex on Aug. 29. By Everdeen Mason My favorite part of this job is creating new things. I love the feeling of laboring with a group of kindred spirits to make ...
US-based Vertex Pharmaceuticals has axed plans to progress its acute pain drug, VX-993, into pivotal development after disappointing Phase II topline results. The NaV1.8 pain signal inhibitor, which ...
Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback